Merck
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merck and other ETFs, options, and stocks.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
MRK News
Many Merck & Co., Inc. (NYSE:MRK) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. Knowing whether insid...
Loading... Loading... Friday, Merck & Co Inc MRK announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, of Keytruda (pembrolizumab) i...
KEYTRUDA plus CRT is the first immunotherapy-based regimen to demonstrate a statistically significant improvement in OS in these patients RAHWAY, N.J., March 1...
Analyst ratings
77%
of 30 ratingsMore MRK News
In the latest trading session, Merck (MRK) closed at $120.51, marking a -1.35% move from the previous day. The stock fell short of the S&P 500, which registered...
Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influenc...
Assessing the Upcoming Dividend and Historical Performance of Merck & Co Inc Merck & Co Inc (NYSE:MRK) recently announced a dividend of $0.77 per share, payabl...
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers RAHWAY, N.J., March 13, 2024--(BUSINESS WIRE)--Merc...
March 13 (Reuters) - Merck & Co said on Wednesday it plans to conduct clinical trials testing its human papillomavirus (HPV) vaccine Gardasil 9 to evaluate the...
RBC Capital tells investors in a research note that following the start of a third potentially pivotal trial in resectable squamous cell carcinoma, two addition...
Shares of Moderna MRNA rose 8.7% on Mar 11, after a government website posted details of the initiation of a phase II/III study on mRNA-4157/V940, its investiga...